Policy | December 16, 2025
Pharma overhaul: EMA hails “Once-in-a-Generation” reform
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
The approval of Augmentin XR, granted to USAntibiotics, directly supports the CNPV program’s goals
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
The project focuses on recovering high-quality polycarbonate, a valuable polymer material used in the construction of the filters
Growing patent filings and tier-2 innovators reflect expanding national research base
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically
Exemplifies commitment of Merck to energy efficiency and sustainable practices in high-performance computing by featuring advanced water-cooling systems and a hybrid cloud infrastructure
Subscribe To Our Newsletter & Stay Updated
